TY - JOUR
AB - PharmacoEconomics & Outcomes News 812, p1 - 22 Sep 2018 implementing multi-indication pricing included: Multi-indication pricing useful for designing incentives to encourage the collection and use drugs with multiple indications of good reliable data; development of improved registries to allow the incorporation of real world Multi-indication pricing (MIP) is a useful tool to evidence in real time; improved coordination of pricing determine the relative prices of drugs for multiple negotiations at the national level, with compatibility indications with different values, say authors of an between hospitals and regions in decentralised article published in PharmacoEconomics. countries, coordination at the hospital level with usage Multi-indication pricing can be a potential solution for monitored in electronic medical records, and some medicines approved for multiple indications, where coordination at a European level; more transparency drugs deliver different values across indications, disease around funding; flexibility to accommodate new states, and patient subpopulations in the same evidence and new indications in contractual pricing indication, whether used alone or in combination with arrangements; and further R&D to model the budget another therapy. This analysis assessed advantages and impact of multi-indication pricing, explore the impact on disadvantages of multi-indication pricing compared with price competition, and investigate surplus 
TI - Multi-indication pricing useful for drugs with multiple indications
JF - PharmacoEconomics & Outcomes News
DO - 10.1007/s40274-018-5268-5
DA - 2018-09-22
UR - https://www.deepdyve.com/lp/springer-journals/multi-indication-pricing-useful-for-drugs-with-multiple-indications-QV9Ywlv47p
SP - 1
EP - 1
VL - 812
IS - 1
DP - DeepDyve
ER -